References
- Akagi M, Kawaguchi M, Liu W, et al (2003). Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer, 88, 796-802. https://doi.org/10.1038/sj.bjc.6600811
- Almo SC, Pollard TD, Way M, et al (1994). Purification, characterization and crystallization of Acanthamoeba profiling expressed in Escherichia coli. J Mol Biol, 236, 950-2. https://doi.org/10.1006/jmbi.1994.1200
- Bergers G, Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 3, 401-10. https://doi.org/10.1038/nrc1093
- Candiano G, Bruschi M, Musante L, et al (2004). Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis, 25, 1327-33. https://doi.org/10.1002/elps.200305844
- Capdevila J, Elez E, Peralta S, et al (2008). Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Rev Anticancer Ther, 8, 1223-36. https://doi.org/10.1586/14737140.8.8.1223
- Cervantes A, Rosello' S, Roda D, et al (2008). The treatment of advanced gastric cancer: current strategies and future perspectives. Ann Oncol, 19, v103-7. https://doi.org/10.1093/annonc/mdn321
- Colorectal Cancer Collaborative Group (2000). Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ, 321, 531-5. https://doi.org/10.1136/bmj.321.7260.531
- Devineni N, Minamide LS, Niu M, et al (1999). Quantitative analysis of G-actin binding proteins and the G-actin pool in developing chick brain. Brain Res, 823, 129-40. https://doi.org/10.1016/S0006-8993(99)01147-6
- Di Nardo A, Gareus R, Kwiatkowski D, et al (2000). Alternative splicing of the mouse profilin II gene generates functionally different profilin isoforms. J Cell Sci, 113, 3795-803.
- Fan S, Ramalingam SS, Kauh J, et al (2009). Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues. Cancer Biol Ther, 8, 1463-9. https://doi.org/10.4161/cbt.8.15.8960
- Ferrara N, Davis-Smyth T (1997). The biology of vascular endothelial growth factor. Endocr Rev, 18, 4-25. https://doi.org/10.1210/er.18.1.4
- Gordon MS, Margolin K, Talpaz M, et al (2001). Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol, 19, 843-50.
- Groves E, Rittinger K, Amstutz M, et al (2010). Sequestering of Rac by the Yersinia effector YopO blocks Fcgamma receptor-mediated phagocytosis. J Biol Chem, 285, 4087-98. https://doi.org/10.1074/jbc.M109.071035
- Hao-AiShui, Shung-TaiHo, Jhi-Joung Wang, et al (2007). Proteomic analysis of spinal protein expression in rats exposed to repeated intrathecal morphine injection. Proteomics, 7, 796-803. https://doi.org/10.1002/pmic.200600699
- Hicklin DJ, Ellis LM (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Clin Oncol, 23, 1011-27.
- Hurwitz H, Fehrenbacher L, Novotny W, et al (2004). Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42. https://doi.org/10.1056/NEJMoa032691
- Inai T, Mancuso M, Hashizume H, et al (2004). Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol, 165, 35-52. https://doi.org/10.1016/S0002-9440(10)63273-7
- Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62. https://doi.org/10.1126/science.1104819
- Lincoln DT, Singal PK, Al-Banaw A (2007). Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation. Anticancer Res, 27, 4201-18.
- Marino N, Zollo M (2007). Understanding h-prune biology in the fight against cancer. Clin Exp Metastasis, 24, 637-45. https://doi.org/10.1007/s10585-007-9109-3
- Nakamura K, Zhang X, Kuramitsu Y, et al (2006). Analysis on heat stress-induced hyperphosphorylation of stathmin at serine 37 in Jurkat cells by means of two-dimensional gel electrophoresis and tandem mass spectrometry. J Chromatogr A, 1106, 181-9. https://doi.org/10.1016/j.chroma.2005.12.068
- Nakamura T, Tabuchi Y, Ohno M (1998). Relations of nm23 expression to clinicopathologic variables and proliferative activity of gastric cancer lesions. Cancer Detect Prev, 22, 246-50. https://doi.org/10.1046/j.1525-1500.1998.0OA27.x
- Ohira K, Kumanogoh H, Sahara Y, et al (2005). A truncated tropomyosin-related kinase B receptor, T1, regulates glial cell morphology via Rho GDP dissociation inhibitor 1. J Neurosci, 25, 1343-53. https://doi.org/10.1523/JNEUROSCI.4436-04.2005
- Patel N, Sun L, Moshinsky D, et al (2003). A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. J Pharmacol Exp Ther, 306, 838-45. https://doi.org/10.1124/jpet.103.052167
- Raffaniello R, Fedorova D, Ip D, et al (2009). Hsp90 Co-localizes with Rab-GDI-1 and regulates agonist-induced amylase release in AR42J cells. Cell Physiol Biochem, 24, 369-78. https://doi.org/10.1159/000257429
- Raffaniello RD, Raufman JP(1999). Cytosolic RAB3D is associated with RAB escortprotein (REP), not RAB-GDP dissociation inhibitor (GDI), in dispersed chief cells from guinea pig stomach. J Cell Biochem,72, 540-8. https://doi.org/10.1002/(SICI)1097-4644(19990315)72:4<540::AID-JCB9>3.0.CO;2-D
- Shevchenko A, Wilm M, Vorm O, et al (1996). Mass spectrometric sequencing of proteins from silver stained polyacrylamide gels. Anal Chem, 68, 850-85. https://doi.org/10.1021/ac950914h
- Tahara E (2004). Genetic pathways of two types of gastric cancer. IARC Sci Publ, 157, 327-49.
- Tee YT, Chen GD, Lin LY, et al (2006). Nm23-H1: a metastasisassociated gene. Taiwan J Obstet Gynecol, 45, 107-13. https://doi.org/10.1016/S1028-4559(09)60206-0
- Tong RT, Boucher Y, Kozin SV, et al (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res, 64, 3731-6. https://doi.org/10.1158/0008-5472.CAN-04-0074
- Willett CG, Boucher Y, Tomaso ED, et al (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10, 145-7. https://doi.org/10.1038/nm988
- Wildiers H, Guetens G, Boeck GD, et al (2003). Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer, 88, 1979-86. https://doi.org/10.1038/sj.bjc.6601005